PainReform Ltd.
PainReform Ltd. (PRFX) Stock Overview
Explore PainReform Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.8M
P/E Ratio
-0.14
EPS (TTM)
$-32.16
ROE
-16.89%
PRFX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PainReform Ltd. (PRFX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 33.40, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.67.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.14 and a market capitalization of 2.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Ehud Geller
2
65 Yigal Alon Street, Tel Aviv
2020